Medytox Receives Approval for Phase 3 Clinical Trial of Fat-Dissolving Injection 'MT921'

7 Domestic Medical Institutions, 240 Patients Targeted

[Image source=Yonhap News]

[Asia Economy Reporter Kim Ji-hee] Medytox announced on the 18th that its clinical phase 3 trial plan (IND) for ‘MT921,’ a lipolysis injection being developed as its first synthetic new drug, was approved by the Ministry of Food and Drug Safety on the 16th. Following this approval, Medytox plans to conduct clinical trials on 240 patients with moderate to severe submental fat at seven medical institutions in Korea.

MT921, developed independently by Medytox, is an injection that efficiently breaks down fat in the body. Unlike existing products on the market, it is evaluated as having excellent market competitiveness by reducing side effects such as swelling and bruising.

Joo Hee-seok, Executive Director of Medytox, said, "MT921 is the first synthetic new drug that consolidates Medytox’s research and development (R&D) capabilities, and it is a next-generation lipolysis injection that improves side effects such as swelling and bruising found in existing products. Since the application field of lipolysis injections is closely related to Medytox’s main businesses of toxins and fillers, we expect it to provide significant synergy and greatly contribute to sales growth in the future."

Meanwhile, in addition to MT921, Medytox has various pipelines for new drug development, including MT106 (anticancer agent), MT912 (macular degeneration), MT971 (inflammatory bowel disease), and MT981 (solid tumors).

This content was produced with the assistance of AI translation services.